Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA
Summary Financials
RIGEL PHARMACEUTICALS INC — SlamSEC
Revenue
$116.9M
-2.8% YoY
FY 2025
Adj. EBITDA
-$19.3M
-16.5% margin
FY 2025
Net Income
-$25.1M
-21.5% margin
FY 2025
EPS (Diluted)
-$1.44
FY 2025
Stock Price
$28.76
-0.3%
2026-03-10
52W Range
$15.50 – $52.24
P/E Ratio
-20.0x
Market Cap
$531.3M
Cash
$56.7M
FY 2025
Total Debt
$52.5M
FY 2025
Net Cash
$4.2M
FY 2025
Enterprise Value
$527.0M
Debt / EBITDA
0.2x
FY 2025
EV / EBITDA
-27.4x
Employees
—
Rigel is a blue supergiant star in the equatorial constellation of Orion. It has the Bayer designation β Orionis, which is Latinized to Beta Orionis and abbreviated Beta Ori or β Ori.